Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SMT-M01
- Development stage
- Preclinical
- Lead developer
- Somite Therapeutics
- Modality
- Cell Therapies
01
Overview
SMT-M01 is an investigational AI-enabled cell replacement therapy being developed by Somite Therapeutics for Duchenne muscular dystrophy, designed to be mutation-agnostic and to restore muscle function by replacing lost or dysfunctional muscle precursor cells. The program leverages Somite’s AlphaStem AI platform to optimize production and differentiation of human cells for therapy, and has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for DMD.[2][3][1][5] Somite has partnered with OmniaBio for process development, iPSC-derived myogenic satellite cell differentiation, and manufacturing activities to advance SMT-M01 toward first-in-human studies.[7]
Beyond the preview
Go deeper on SMT-M01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SMT-M01.